Unknown

Dataset Information

0

A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies.


ABSTRACT: Immunotherapy that targets N-linked glycans has not yet been developed due in large part to the lack of specificity of N-linked glycans between normal and malignant cells. N-Glycan chains are synthesized by the sequential action of glycosyl transferases in the Golgi apparatus. It is an overwhelming task to discover drug-like inhibitors of glycosyl transferases that block the synthesis of specific branching processes in cancer cells, killing tumor cells selectively. It has long been known that N-glycan biosynthesis can be inhibited by disruption of the first committed enzyme, dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 (DPAGT1). Selective DPAGT1 inhibitors have the promising therapeutic potential for certain solid cancers that require increased branching of N-linked glycans in their growth progressions. Recently, we discovered that an anti-Clostridium difficile molecule, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) showed DPAGT1 inhibitory activity with the IC50 value of 0.25??M. It was confirmed that APPB inhibits N-glycosylation of ?-catenin at 2.5?nM concentration. A sharp difference between APPB and tunicamycin was that the hemolytic activity of APPB is significantly attenuated (IC50?>?200??M RBC). Water solubility of APPB is >350-times greater than that of tunicamycin (78.8?mg/mL for APPB, <0.2?mg/mL for tunicamycin). A novel DPAGT1 inhibitor, APPB selectively inhibits growth of the solid tumors (e.g. KB, LoVo, SK-OV-3, MDA-MB-432S, HCT116, Panc-1, and AsPC-1) at low ?M concentrations, but does not inhibit growth of a leukemia cell (L1210) and the healthy cells (Vero and HPNE) at these concentrations. In vitro metabolic stability using rat liver microsomes indicated that a half-life (t 1/2) of APPB is sufficiently long (>60?min) for in vivo studies (PK/PD, safety profiles, and in vivo efficacy) using animal models. We have refined all steps in the previously reported synthesis for APPB for larger-scale. This article summarizes protocols of gram-scale synthesis of APPB and its physicochemical data, and a convenient DPAGT1 assay. •Remember that the abstract is what readers see first in electronic abstracting & indexing services.•This is the advertisement of your article. Make it interesting, and easy to be understood.•Be accurate and specific, keep it as brief as possible.

SUBMITTER: Mitachi K 

PROVIDER: S-EPMC6812346 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies.

Mitachi Katsuhiko K   Kurosu Shou M SM   Gillman Cody D CD   Yun Hyun Gi HG   Clemons William M WM   Kurosu Michio M  

MethodsX 20190927


Immunotherapy that targets <i>N</i>-linked glycans has not yet been developed due in large part to the lack of specificity of <i>N</i>-linked glycans between normal and malignant cells. <i>N</i>-Glycan chains are synthesized by the sequential action of glycosyl transferases in the Golgi apparatus. It is an overwhelming task to discover drug-like inhibitors of glycosyl transferases that block the synthesis of specific branching processes in cancer cells, killing tumor cells selectively. It has lo  ...[more]

Similar Datasets

| S-EPMC4035711 | biostudies-literature
| S-EPMC6447083 | biostudies-literature
| S-EPMC3994091 | biostudies-literature
| S-EPMC7011796 | biostudies-literature
| S-EPMC4685759 | biostudies-literature
| S-EPMC6142761 | biostudies-literature
| S-EPMC6272704 | biostudies-literature
| S-EPMC3068231 | biostudies-literature
| S-EPMC5964670 | biostudies-literature
| S-EPMC2979463 | biostudies-literature